Nammi Therapeutics Featured in Los Angeles Business Journal

Updated: Feb 9, 2023

Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and CEO of Nammi Therapeutics, and highlighted the most recent achievements of the company including the CIRM grant and Amgen Golden Ticked award.

https://labusinessjournal.com/featured/nammis-cancer-immunotherapy-technology-garners-award-and-stem-cell-grant/

Recent Posts

See All

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma

Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...

Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...

Amgen and BioLabs LA Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket

Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in...

Nammi Therapeutics Featured in Los Angeles Business Journal

Recent Posts

Comments